COMP <GO>
ANAB vs UNH // REVENUE GROWTH (YOY)
AnaptysBio Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: ANAB 4
— UNH 5
▲ REVENUE GROWTH (YOY) LEADER: ANAB
LAST: $48.28 (-0.74%) • MKT CAP: $1.44B
revenue-growth
157.00%
LAST: $406.97 (-0.96%) • MKT CAP: $368.83B
revenue-growth
6.46%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ANAB VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ANAB | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 88.57% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 85.00% | 11.47% | +73.53 | ANAB | /roic <GO> |
| EV/EBITDA & P/E Valuation | 5.7x | 16.4x | -10.75 | ANAB | /valuation <GO> |
| Free Cash Flow Yield | 1.36% | 6.48% | -5.12 | UNH | /fcf-yield <GO> |
| Operating Margin | 75.00% | 4.82% | +70.18 | ANAB | /operating-margins <GO> |
| Net Profit Margin | -5.60% | 3.14% | -8.74 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 157.00% | 6.46% | +150.54 | ANAB | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 3.12 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.74% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.0 | 59.2 | -11.20 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.33 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 17.7x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.44B | $368.83B | -$367.39B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ANAB REV | UNH REV | ANAB GROSS % | UNH GROSS % | ANAB FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $234.6M | $447.57B | — | 88.7% | $19.6M | $16.07B |
| FY 2024 | $91.3M | $400.28B | — | 88.3% | -$135.7M | $20.70B |
| FY 2023 | $17.2M | $371.62B | — | 89.6% | -$120.8M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ANAB // BETA —
UNH // BETA 0.33